FULVENAT 250MG INJECTION

Fulvenat 250mg injection contains fulvestrant as its active ingredient. This antineoplastic medication is classified as an estrogen receptor antagonist. Estrogen, a female sex hormone, can sometimes contribute to the development of breast cancer. This medication is utilized on its own to treat postmenopausal women diagnosed with a specific type of breast cancer known as estrogen receptor-positive breast cancer, which may be locally advanced or have metastasized to other areas of the body. Additionally, it is prescribed in conjunction with other anti-cancer therapies for women with certain types of breast cancer referred to as hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer, which is also locally advanced or has spread to other regions of the body.

Do not use this injection if you are allergic to fulvestrant or any of its components, if you are pregnant or breastfeeding, or if you have severe liver issues. Prior to starting treatment, inform your healthcare provider if you have kidney or liver conditions, bone disorders, bleeding issues, or heart diseases. Fulvenat 250mg injection is not intended for use in children and adolescents under 18 years of age. Notify your doctor if you experience any allergic reactions, such as swelling of the face, lips, tongue, or throat, after receiving this injection.

Common side effects associated with Fulvenat 250mg injection include pain or inflammation at the injection site, abnormal liver enzyme levels, nausea, headaches, cough, fatigue or weakness, joint and muscle discomfort, hot flashes, hair loss, and skin rashes. Your physician may recommend specific blood tests while you are undergoing treatment with this injection. This medication may elevate your risk of bleeding and liver failure. Female patients who are capable of becoming pregnant should employ effective contraception during treatment and for two years following the final dose.